• 1
    Bergman U, Wiholm B-E. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981;20:193200.
  • 2
    Maxwell S, Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009;4:e4439.
  • 3
    Mölstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama program. Lancet Infect Dis 2008;8:12532.
  • 4
    The rational use of drugs. Report of the conference of experts Nairobi; 1985, 25–29 November. World Health Organisation, Geneva 1987. 2010 (last accessed on 19 February 2011).
  • 5
    McGinn D, Godman B, Lonsdale J, Josalind W, Wettermark B, Haycoux A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:7385.
  • 6
    Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int J Clin Pract 2009;63:13206.
  • 7
    Fijn R, Brouwers JR, Knaap RJ, De Jong-Van Den Berg LT. Drug and Therapeutics (DT) committees in Dutch hospitals: a nationwide survey of structure, activities and drug selection procedures. Br J Clin Pharmacol 1999;48:23946.
  • 8
    Sjöqvist F, Bergman U, Dahl M-L, Gustafsson LL, Hensjö LO. Drug and Therapeutics committees: a Swedish experience. WHO Drug Inf 2002;16:20713.
  • 9
    Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L et al. Clinical pharmacology in research, teaching and health care. Basic Clin Pharmacol Toxicol 2010;107:5319.
  • 10
    World Health Organization. The Selection of Essential Drugs: Report of a WHO Expert Committee. Technical Report Series no 615. World Health Organisation Press, Geneva, 1977.
  • 11
    Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:172.
  • 12
    Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998;317:85861.
  • 13
    Wettermark B, Haglund K, Gustafsson LL, Persson PM, Bergman U. A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiol Drug Saf 2005;14:57988.
  • 14
    Wilson RP, Hatcher J, Barton S, Walley T. Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study. BMJ 1996;313:5959.
  • 15
    Godman B, Wettermark B, Andersson K, Hoffmann M, Haycox A, Bertele V et al. The recent Swedish experience in moderating drug expenditure: a global example. Expert Rev Pharmacoecon Outcomes Res 2009;9:6583.
  • 16
    Soumerai SB, Avorn J. Principles of educational outreach (‘academic detailing’) to improve clinical decision making. JAMA 1990;263:54956.
  • 17
    Helin-Salmivaara A, Huupponen R, Klaukka T, Hoppu K. Focusing on changing clinical practice to enhance rational prescribing/collaboration and networking enable comprehensive approaches. Health Policy 2003;66:110.
  • 18
    Kotler P. Marketing Management, 10th edn. Upper Saddle River, New Jersey, 2000.
  • 19
    McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:263545.
  • 20
    Petrie JC, Grimshaw JM, Bryson A. The Scottish Intercollegiate Guidelines Network Initiative: getting validated guidelines into local practice. Health Bull 1995;53:3458.
  • 21
    World Health Organization. Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, 2010. (last accessed on 18 February 2011).
  • 22
    Vlahović-Palcevski V, Gantumur M, Radosević N, Palcevski G, Vander Stichele R. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm World Sci 2010;32:1259.
  • 23
    Andersson K, Bergström G, Petzold MG, Carlsten A. Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy 2007;81:37694.
  • 24
    Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Åberg H et al. Drug utilization 90%– a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 1998;54:1138.
  • 25
    Wettermark B, Pehrsson Å, Jinnerot D, Bergman U. Drug utilisation 90% profiles – a useful tool for quality assessment of prescribing in primary healthcare in Stockholm. Pharmacoepidemiol Drug Saf 2003;13:499510.
  • 26
    Wettermark B, Pehrsson Å, Juhasz-Haverinen M, Veg M, Edlert M, Törnwall-Bergendahl G et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care 2009;17:17989.
  • 27
    Avorn J. Keeping science on top in drug evaluation. N Engl J Med 2007;357:6335.
  • 28
    Sjöqvist F. More stringent requirements in connection with the choice of drugs. Members of the drug committees in Stockholm deliver an annual declaration of challengeability. Lakartidningen 2001;95;5413. In Swedish.
  • 29
    Rossouw JE, Andersson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:32133.
  • 30
    Sjöborg B, Bäckström T, Arvidsson LB, Andersén-Karlsson E, Blomberg LB, Eiermann B et al. Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region-bridging the gap between knowledge and practice. Int J Med Inform 2007;76:497506.
  • 31
    Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2009;9:47584.
  • 32
    Huttner B, Goossens H, Verheij T, Harbarth S; CHAMP consortium. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis 2010;10:1731.
  • 33
    Rucker TD, Schiff G. Drug formularies: myths-in-formation. Med Care 1990;28:92842.
  • 34
    Suggs LS, Raina P, Gafni A, Grant S, Skilton K, Fan A et al. Family physician attitudes about prescribing using a drug formulary. BMC Fam Pract 2009;10:69.
  • 35
    Armstrong K, Kendall E. Translating knowledge into practice and policy: the role of knowledge networks in primary health care. HIM J 2010;39:917.
  • 36
    Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:70722.
  • 37
    Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010;94:2219.
  • 38
    Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs – the importance of who says what. Fam Pract 2003;20:618.
  • 39
    Zarowitz B, Muma B, Coggan P, Davis G, Barkley GL. Managing the pharmaceutical industry – health systems interface. Ann Pharmacother 2001;35:16618.
  • 40
    Castensson S, Eriksson V, Lindborg K, Wettermark B. A method to include the environmental hazard in drug prescribing. Pharm World Sci 2009;31:2431.